HomeClinical TopicsFDA approves drug for rare metabolic disorder

FDA approves drug for rare metabolic disorder

On Sept. 4, the U.S. Food and Drug Administration (FDA) approved Xuriden (uridine triacetate), the first FDA-approved treatment for patients with hereditary orotic aciduria, a rare metabolic disorder that has been reported in about 20 patients worldwide.

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Most Recent Content